ClinicalTrials.gg

Heart Failure clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 6,334 studies for Heart Failure across more than 10 countries. 1,394 are recruiting or about to start. 4,745 of them are mainly about Heart Failure (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Heart Failure, Systolic: 6,607 studies, 1,452 open.

ClinicalTrials.gov finds 7,938 studies for Heart Failure. How that becomes 6,332 here

This page counts the studies the registry files under Heart Failure, and those it files under no condition that list Heart Failurethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 7,938Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −271Filed under a narrower condition, counted on its own pageHeart Failure, Diastolic 112 · Heart Failure, Systolic 100 · Cardio-Renal Syndrome 52
  3. −465List Heart Failure as a condition, but the registry did not file them under itMost often written as “Chronic Heart Failure” (123), “Heart Failure With Preserved Ejection Fraction” (65), and “Heart Failure With Reduced Ejection Fraction” (50). The registry filed them under other conditions only, most often Atrial Fibrillation (33) and Pulmonary Disease, Chronic Obstructive (29).
  4. −870Match it another way266 name it in the title, 62 in a keyword, and 542 by a synonym or other text the search reads.
  5. 6,332The count on this page729 of them list Heart Failure in their own words; the registry filed them under no condition.

Status

Completed
3,148
Recruiting
967
Status unknown
804
Terminated
451
Not yet recruiting
342
Active, not recruiting
267

Phase

Phase 2
657
Phase 3
482
Phase 4
470
Phase 1
330
Early Phase 1
40

Where

United States
2,157
Germany
600
United Kingdom
482
Canada
453
Italy
449
France
448

Who develops what

Add Heart Failure to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 49 programs from 35 companies, 46 with this as their studies’ main aim; 9 with a live phase 3 study; 8 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Novo Nordisk and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
FurosemideEarlier only
Evidence
  • NCT04384653 · SQ Innovation, Inc. · Phase 2 · comparator · “Furosemide Injection, USP” · registered Apr 2020
  • NCT03901729 · Bayer · Phase 2 · comparator · “Furosemide” · registered Apr 2019
  • NCT03730961 · Bristol-Myers Squibb · Phase 2 · background · “Furosemide” · registered Nov 2018
  • NCT02329834 · Mannkind Corporation · Phase 3 · background · “Furosemide Injection, USP” · registered Dec 2014
  • NCT01210365 · Eurofarma Laboratorios S.A. · Phase 3 · comparator · “Lasix ®” · registered Aug 2010
Boehringer Ingelheim26% of its industry studiesUS: off-patent, 19 generics marketedEU: Proveca Pharma Limited (EMA 2026)00 studies
SpironolactoneEarlier only
Evidence
  • NCT01345656 · Bayer · Phase 2 · comparator · “Spironolactone” · registered Apr 2011
  • NCT01130597 · CSL Limited · Phase 2 · background · “spironolactone” · registered May 2010
CMP Development, LLC25% of its industry studiesUS: off-patent, 15 generics marketedEU: Lipomed (EMA 2023)00 studies
NitroglycerinEarlier only
Evidence
  • NCT03357731 · Bristol-Myers Squibb · Phase 2 · background · “Nitroglycerin (NTG)” · registered Oct 2017
  • NCT00803634 · Novartis · Phase 3 · standard-care · “Standard of Care IV antihypertensive” · registered Dec 2008
MediQuest Therapeutics29% of its industry studiesUS: off-patent, 17 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
HICM-188☆ Track1 live phase-3 study: NCT07496372HELP Therapeutics Co., Ltd.
omecamtiv mecarbil☆ Track1 live phase-3 study: NCT06736574Cytokinetics
vicadrostat☆ Track2 live phase-3 studies: NCT06935370, NCT06424288Boehringer Ingelheim
Qishen Yiqi Dripping Pills 2 bags☆ Track1 live phase-3 study: NCT07687186China Resources Pharmaceutical Group Limited
TNX-103☆ Track3 live phase-3 studies: NCT07436689, NCT07288398, NCT05983250Tenax Therapeutics, Inc.

The 5 in phase 3 with the nearest primary completion, of 49 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (8)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.XTR003 · Sinotau Pharmaceutical Group · Phase 2 main aimNCT07443696 PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy — primary endpoint: the sensitivity and specificity of the experimental group and control group · 40 enrolled
  • 31 Dec 2026 est.Mesenchymal stem cells(HucMSCs) · China Resources Pharmaceutical Group Limited · Phase 2 main aimNCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure — primary endpoint: In phase I, primary outcome will be measured with safety events including DLT, AE, SAE, TEAE, and MACE. In phase II, primary outcome will be measured with the change in LVEF based on CMR detection after 6 months of administration. · 51 enrolled
  • Mar 2027 est.HRS-1893 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07269717 A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction — primary endpoint: Incidence and severity of adverse events (AEs). · 48 enrolled

5 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Heart Failure studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 26 open · Mineralocorticoid receptor antagonists (MRAs) 16 open · Diuretics 12 open · Angiotensin receptor blockers (ARBs) 12 open · Beta blockers 9 open

Coming up

446studies finish main data collection within a year20 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger. 63 (7%) take children under 18. 12 (1%) are for women only and 3 (<1%) for men only; 96 (10%) take healthy volunteers.

Recruiting studies that take each age, of 967
AgeWomenMen
1047 (5%)48 (5%)
18767 (79%)760 (79%)
30839 (87%)831 (86%)
40877 (91%)869 (90%)
50896 (93%)888 (92%)
65935 (97%)924 (96%)
75909 (94%)899 (93%)
85805 (83%)795 (82%)

Across all 6,334 studies, recruiting or not: 10% stop at 75 or younger and 4% at 65; 7% take children; 1% are for women only and 1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Heart Failure studies take

Of 185 phase 2 interventional studies under Heart Failure, half reached primary completion within 29 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo4–36 · 131 studies7 mo2–16 · 77 studies36 mo17–58 · 54 studies
Phase 1/239 mo22–48 · 43 studies——
Phase 229 mo17–47 · 185 studies21 mo14–31 · 74 studies39 mo21–66 · 111 studies
Phase 2/333 mo16–54 · 24 studies——
Phase 339 mo26–57 · 150 studies36 mo20–44 · 63 studies50 mo28–63 · 87 studies
Phase 431 mo22–56 · 183 studies—32 mo22–56 · 164 studies
Interventional, no phase31 mo16–52 · 1,354 studies34 mo18–62 · 236 studies29 mo16–50 · 1,118 studies
Observational41 mo22–89 · 978 studies34 mo20–57 · 182 studies45 mo23–99 · 796 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting21

Show 16 more

Newly registered30

Show 25 more

Studies

Recruiting first, then most recently updated. Showing 50 of 6,334. Browse all 6,334 → or search them.